» Articles » PMID: 24069310

VEZT, a Novel Putative Tumor Suppressor, Suppresses the Growth and Tumorigenicity of Gastric Cancer

Overview
Journal PLoS One
Date 2013 Sep 27
PMID 24069310
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Vezatin (VEZT), an adherens junctions transmembrane protein, was identified as a putative tumor suppressor in our previous study. However, the role of VEZT in tumorigenesis remains elusive. We aimed to clarify its epigenetic regulation and biological functions in gastric cancer. In this study, we show that the expression level of VEZT is involved in lymphatic metastasis, depth of cancer invasion and TNM stage in 104 gastric cancer patients. Bisulfate sequencing polymerase chain reaction (BSP) methods showed that VEZT was hypermethylated in tissues and corresponding blood of gastric cancer patients compared with healthy controls. Helicobacter pylori (H. pylori) infection induces the methylation and silencing of VEZT in GES-1 cells. Restoring VEZT expression in MKN-45 and NCI-N87 gastric cancer cells inhibited growth, invasion and tumorigenesis in vitro and in vivo. Global microarray analysis was applied to analyze the molecular basis of the biological functions of VEZT after VEZT transfection combined with real-time PCR and chromatin immunoprecipitation assay. G protein-coupled receptor 56(GPR56), cell growth, cell division cycle 42(CDC42), migration/invasion and transcription factor 19(TCF19), cell cycle progression, were identified as direct VEZT target genes. TCF19, a novel target of VEZT, was functionally validated. Overexpression of TCF19 in MKN-45 cells increased cell cycle progress and growth ability. This study provides novel insight into the regulation of the VEZT gene, which could represent a potential target for therapeutic anti-cancer strategies.

Citing Articles

Single-cell transcriptomics uncovers EGFR signaling-mediated gastric progenitor cell differentiation in stomach homeostasis.

Takada H, Sasagawa Y, Yoshimura M, Tanaka K, Iwayama Y, Hayashi T Nat Commun. 2023; 14(1):3750.

PMID: 37386010 PMC: 10310803. DOI: 10.1038/s41467-023-39113-0.


Iroquois Family Genes in Gastric Carcinogenesis: A Comprehensive Review.

Dos Santos E, Petrone I, Binato R, Abdelhay E Genes (Basel). 2023; 14(3).

PMID: 36980893 PMC: 10048635. DOI: 10.3390/genes14030621.


Immunotherapeutic Value of Transcription Factor 19 (TCF19) Associated with Renal Clear Cell Carcinoma: A Comprehensive Analysis of 33 Human Cancer Cases.

Cheng X, Hou J, Wen X, Dong R, Lu Z, Jiang Y J Oncol. 2022; 2022:1488165.

PMID: 36111242 PMC: 9470357. DOI: 10.1155/2022/1488165.


Performance of DNA Methylation on the Molecular Pathogenesis of in Gastric Cancer; targeted therapy approach.

Vahidi S, Mirzajani E, Norollahi S, Aziminezhad M, Samadani A J Pharmacopuncture. 2022; 25(2):88-100.

PMID: 35837145 PMC: 9240405. DOI: 10.3831/KPI.2022.25.2.88.


The role of GPR56/ADGRG1 in health and disease.

Singh A, Lin H Biomed J. 2021; 44(5):534-547.

PMID: 34654683 PMC: 8640549. DOI: 10.1016/j.bj.2021.04.012.


References
1.
Koon H, Ippolito G, Banham A, Tucker P . FOXP1: a potential therapeutic target in cancer. Expert Opin Ther Targets. 2007; 11(7):955-65. PMC: 4282158. DOI: 10.1517/14728222.11.7.955. View

2.
Kang G, Lee S, Kim J, Jung H . Profile of aberrant CpG island methylation along multistep gastric carcinogenesis. Lab Invest. 2003; 83(4):519-26. DOI: 10.1097/01.lab.0000064704.53132.65. View

3.
Choi I, Wu T . Epigenetic alterations in gastric carcinogenesis. Cell Res. 2005; 15(4):247-54. DOI: 10.1038/sj.cr.7290293. View

4.
Bahloul A, Simmler M, Michel V, Leibovici M, Perfettini I, Roux I . Vezatin, an integral membrane protein of adherens junctions, is required for the sound resilience of cochlear hair cells. EMBO Mol Med. 2010; 1(2):125-38. PMC: 3378116. DOI: 10.1002/emmm.200900015. View

5.
Quackenbush J . Microarray analysis and tumor classification. N Engl J Med. 2006; 354(23):2463-72. DOI: 10.1056/NEJMra042342. View